Following development by the GM Diabetes Oversight Group and review by CRG, we now seek comments on a draft commissioning statement for metformin for preventing type 2 diabetes in people living with non-diabetic hyperglycaemia.
This consultation will run for six weeks and closes at 5pm on Wednesday 2nd July 2025. To take part, visit the consultations page.